Ardelyx Inc. (ARDX)
Ardelyx: Improved Outlook For Ibsrela And Xphozah
The share price of Ardelyx has finally broken the year-long downtrend after a strong second quarter earnings report. Ibsrela returned to stronger topline growth in Q2 and the company raised the full-year net sales guidance range for the product by $10 million at the mid-point. Xphozah is showing resilience post-Medicare access loss, with commercial sales stabilizing and the product seeing increased demand and sales growth in Q2 versus Q1.
Ardelyx, Inc. (ARDX) Q2 2025 Earnings Call Transcript
Ardelyx, Inc. (NASDAQ:ARDX ) Q2 2025 Earnings Conference Call August 4, 2025 4:30 PM ET Company Participants Caitlin Lowie - Vice President of Corporate Communications & Investor Relations Eric Duane Foster - Chief Commercial Officer Justin A. Renz - Chief Financial & Operations Officer Michael G.
Ardelyx (ARDX) Reports Q2 Loss, Tops Revenue Estimates
Ardelyx (ARDX) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.07 per share a year ago.
Earnings Preview: Ardelyx (ARDX) Q2 Earnings Expected to Decline
Ardelyx (ARDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ardelyx: Revenue Misses And Losses Widen Amid XPHOZAH Uncertainty
Ardelyx's Q1 earnings reveal a sequential drop in revenue and a sharp rise in SG&A expenses, leading to a substantial operational loss. The company faces reimbursement challenges for XPHOZAH, raising concerns about its future profitability and market position. Despite having solid liquidity, Ardelyx's high cash burn rate and debt pose sustainability risks, making its current valuation seem inflated.
Ardelyx, Inc. (ARDX) Q1 2025 Earnings Call Transcript
Ardelyx, Inc. (NASDAQ:ARDX ) Q1 2025 Earnings Conference Call May 1, 2025 4:30 PM ET Company Participants Caitlin Lowie - Vice President of Corporate Communications and Investor Relations Mike Raab - President and CEO Eric Foster - Chief Commercial Officer Justin Renz - Chief Financial and Operations Officer Conference Call Participants Louise Chen - Scotiabank Ryan Deschner - Raymond James Dennis Ding - Jefferies Joseph Thome - TD Cowen Roanna Ruiz - Leerink Partners Julian Harrison - BTIG Aydin Huseynov - Ladenburg Operator Good day everyone and welcome to the Ardelyx's First Quarter 2025 Earnings. All participants will be in a listen-only mode.
Compared to Estimates, Ardelyx (ARDX) Q1 Earnings: A Look at Key Metrics
Although the revenue and EPS for Ardelyx (ARDX) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Ardelyx (ARDX) Reports Q1 Loss, Misses Revenue Estimates
Ardelyx (ARDX) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to loss of $0.11 per share a year ago.
Undercovered Dozen: Ardelyx, Aviva, Nutrien, Heartland Express +
The 'Undercovered' Dozen series highlights 12 lesser-covered stocks, providing investment ideas and sparking discussions on their potential. Edtech company Udemy is seen as on the rise and is a Strong Buy from Weebler Finance. Jumia Technologies shows resilience and growth potential in African e-commerce, despite market skepticism and low stock prices.
Ardelyx: Limited Pipeline, Rising Costs, And Uncertain Growth Ahead (Downgrade)
Ardelyx, Inc. faces significant challenges in 2025 due to Xphozah's reimbursement issues and modest growth from Ibsrela, prompting a downgrade to "sell" and "market underperform." Xphozah's inclusion in a bundled system and loss of Medicare Part D coverage limits revenue potential, despite the company's $750 million annual sales guidance. Increased SG&A expenses and looming debt obligations raise concerns about Ardelyx's ability to achieve consistent profitability and fund necessary R&D investments.
3 Biotech/Healthcare Names Under $10 I Am Buying Now
Today, I am highlighting three biotech/healthcare stocks that currently trade under $10 a share after some recent weakness. ! am slowly accumulating each of these names on these dips both straight equity purchases and covered call orders. All have had some recent positive despite the action in the shares and have good longer-term prospects.
Ardelyx, Inc. (ARDX) Q4 2024 Earnings Call Transcript
Call End: Ardelyx, Inc. (NASDAQ:ARDX ) Q4 2024 Earnings Conference Call February 20, 2025 8:00 A.M. ET Company Participants Caitlin Lowie - Vice President of Corporate Communications & Investor Relations Mike Raab - President & CEO Eric Foster - Chief Commercial Officer Justin Renz - Chief Financial & Operations Officer Conference Call Participants Yigal Nochomovitz – Citigroup Dennis Ding – Jefferies Laura Chico - Wedbush Securities Joseph Thome - TD Cowen Roanna Ruiz - Leerink Partners Julian Harrison – BTIG Ryan Deschner - Raymond James Thomas Yip - H.C.
